FAP IL12
Alternative Names: FAP-IL12Latest Information Update: 27 Mar 2023
At a glance
- Originator Philogen
- Class Antibodies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Fibroblast activation protein antagonists; Interleukin-2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 27 Mar 2023 Discontinued - Preclinical for Unspecified in Italy (Parenteral) (Philogen pipeline, March 2023)
- 17 Feb 2022 FAP IL12 is available for licensing as of 28 Jan 2022. https://www.philogen.com/work-with-us/partnering/
- 28 Jan 2022 Preclinical trials in Unspecified in Italy (Parenteral) before January 2022 (Philogen pipeline , January 2022)